JS
Therapeutic Areas
Eagle Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BARHEMSYS® (amisulpride) injection | Postoperative nausea and vomiting (PONV) | Approved/Commercial |
| BYFAVO® (remimazolam) for injection | Induction and maintenance of procedural sedation | Approved/Commercial |
| First-in-class NCE Pipeline | Oncology and Critical Care | Not Specified |
Leadership Team at Eagle Pharmaceuticals
MG
Michael Graves
Chief Executive Officer & Chairman of the Board
CK
Christopher Krawtschuk
Chief Financial Officer
DH
Debra Hussain
Head of Commercial for Acute Care/Hospital
DO
Daniel O’Connor
Chief Strategy Officer & Head of Corporate Development
RA
Richard A. Edlin, J.D.
Board Member
RL
Robert L. Glenning
Board Member
LB
Luciana Borio, MD
Board Member
SR
Steven Ratoff
Board Member